Pharmacy practice issues with targeted therapy for lung cancer

Area of Science:

• Oncology
• Pharmacology
• Health Economics

Background:

• Lung cancer remains a leading cause of cancer mortality globally, with a low five-year survival rate despite treatment advancements.
• Targeted therapies, driven by molecular biology insights, offer new treatment avenues for lung cancer.
• Epidermal Growth Factor Receptor (EGFR) is a key target in non-small cell lung cancer (NSCLC), prevalent in adenocarcinoma and squamous cell subtypes.

Purpose of the Study:

• To discuss the financial and reimbursement challenges associated with targeted lung cancer therapies.
• To examine the implications of these drug costs and reimbursement issues on pharmacy practice.
• To highlight the role of pharmacists in managing patients receiving oral targeted agents.

Main Methods:

• Review of drug costs and reimbursement policies for targeted lung cancer therapies.
• Analysis of the impact on pharmacy services and patient management.
• Discussion of gefitinib, an EGFR tyrosine kinase inhibitor, as a case study for oral targeted therapy.

Main Results:

• Gefitinib demonstrates activity and tolerable toxicity in NSCLC patients.
• The oral administration of gefitinib necessitates significant patient compliance and education.
• Pharmacy practice is increasingly involved in the comprehensive management of patients on targeted lung cancer therapies.

Conclusions:

• Drug costs and reimbursement are significant barriers to accessing targeted lung cancer treatments.
• Pharmacists play a vital role in ensuring patient adherence and optimizing outcomes for oral targeted therapies.
• Effective pharmacy practice is essential for navigating the complexities of targeted cancer drug management.